Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.0925
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 88806065612.0
- FreeCF/Share 7.1636
- PFCF 6.0918
- PE 17.5851
- Debt/Assets 0.5379
- DivYield 0.0568
- ROE 0.2957
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Rates Going Lower Next Week: Our Top 5% Dividend Picks Could Soar
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
October's 5 Dividend Growth Stocks With Yields Up To 8.33%
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Every month, we screen for high-yield dividend yields, but those that also deliver relatively consistent growth with regular dividend increases. The parameters of the screening also include dividend safety, which factors in payout ratios, debt and free cash flow as some key metrics. While these names screen highly, it is important to remember that it is only an initial dive; more due diligence is necessary before making any investment decision.
Read More
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
REDMOND, Wash. and PRINCETON, N.J.
Read More
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry's gain of 4.8%.
Read More
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from new drugs like Breyanzi offset legacy drug declines. Political risks are manageable for BMY as a US-based company, with potential policy changes likely to have limited impact on its bottom line.
Read More
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Billionaires Are Piling Into United Health Group and These 2 Stocks
Published: October 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
UnitedHealth Group (NYSE:UNH ), Bristol-Myers Squibb (NYSE:BMY) and Fiserv (NYSE:FI) have been getting plenty of attention from big name investors.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Read More
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Read More
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - President of Cell Therapy Organization Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
Read More
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Read More
Bristol Myers to sell 60% stake in China joint venture
Published: September 17, 2025 by: Reuters
Sentiment: Neutral
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
Read More
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
Read More
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
Read More
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).
Read More
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
Published: September 08, 2025 by: Reuters
Sentiment: Positive
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.
Read More
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hodgkin lymphoma called Breyanzi reached $344 million in Q2 2025, increasing by more than 100% year-on-year. Moreover, Bristol-Myers may expand its label on December 5, 2025, and become the first CAR T-cell therapy in the treatment of relapsed/refractory marginal zone lymphoma.
Read More
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Negative
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in its legacy segment. Notably, BMY's robust profitability and a sector-leading dividend yield help to secure buy-in from income investors with the patience to ride out the near-term turbulence.
Read More
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100